↓ Skip to main content
Embed badge What is this page?

Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations

Overview of attention for article published in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, January 2012
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
16 Mendeley
citeulike
1 CiteULike

What is this page?

Summary Twitter Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations
Published in
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, January 2012
DOI 10.2147/dmso.s15404
Pubmed ID
22291471
Authors

Leon Fogelfeld, Uy, Juanito, Guerra Yannis

Abstract

We have now at our disposal the new rapid-acting insulin analogs, of which insulin lispro was the first to become commercially available. While the differences in pharmacokinetic and pharmacodynamic characteristics are indisputable, the clinical benefits attained by these changes have not been as clear. In the present review, we discuss the structure, pharmacology, and landmark studies related to insulin lispro. The clinical characteristics of insulin lispro are compared with those of insulin regular and other insulin analogs in different clinical situations. Also included are the aspects of quality of life and cost-effectiveness that may modify the modern practitioner's decision to adopt one type of insulin over another.

View on publisher site

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Italy 1 6%
Unknown 15 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 25%
Student > Master 2 13%
Student > Bachelor 1 6%
Lecturer > Senior Lecturer 1 6%
Other 1 6%
Other 1 6%
Unknown 6 38%
Readers by discipline Count As %
Medicine and Dentistry 5 31%
Pharmacology, Toxicology and Pharmaceutical Science 2 13%
Biochemistry, Genetics and Molecular Biology 1 6%
Computer Science 1 6%
Nursing and Health Professions 1 6%
Other 0 0%
Unknown 6 38%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 February 2012.
All research outputs
#15,247,248
of 22,671,366 outputs
Outputs from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#509
of 989 outputs
Outputs of similar age
#163,167
of 244,075 outputs
Outputs of similar age from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#4
of 7 outputs
Altmetric has tracked 22,671,366 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 989 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 244,075 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.

This page is provided by Altmetric.